FDA Grants Lurbinectedin Orphan Drug Status for SCLC

August 6, 2018 – The FDA has granted lurbinectedin (PM1183) an orphan drug designation for the treatment of patients with small cell lung cancer (SCLC), according to PharmaMar, the manufacturer of the marine-derived treatment. The Orphan Drug program is intended to facilitate the development and review of novel therapies for the treatment of patients with rare diseases or conditions that affect fewer than 200,000 people in the United States. Data were presented at the … (leggi tutto)